[1] Ott JJ,Stevens GA,Groeger J,et al. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine,2012,30:2212-2219.
[2] Fattovich G,Bortolotti F,Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol,2008,48:335-352.
[3] Liaw YF,Leung N,Kao JH,et al. Asian-pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int,2008,2:263-283.
[4] 王贵强,王福生,成军,等. 慢性乙型肝炎防治指南(2015年版). 中华实验和临床感染病杂志(电子版),2015,05:570-589.
[5] 刘林华,陈新月. 抗乙型肝炎病毒新药—恩替卡韦. 国际流行病学传染病学杂志,2006,01:58-60+75.
[6] 中华医学会肝病学分会,中华医学会感染病学分会. 慢性乙型肝炎防治指南2010年更新版. 中华实验和临床感染病杂志(电子版),2011,01:79-100.
[7] 应灵军,陈华忠,张建伟,等. 代偿期乙型肝炎肝硬化患者长期抗病毒治疗后临床特点和肝脏组织学改变. 中华临床感染病杂志,2016,01:13-18.
[8] Schiff ER, Lee SS, Chao YC,et al. Long-term treatment with entecavir induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis B. Clin Gastroenterol Hepatol,2011,09:274-276.
[9] Xu Y,Zhang YG,Wang X,et al. Long-term antiviral efficacy of entecavir and liver histology improvement in Chinese patients with hepatitis B virus-related cirrhosis. World J Gastroenterol,2015,21:7869-7876.
[10] Kuo YH,Lu SN,Chen CH,et al. The changes of liver stiffness and its associated factors for chronic hepatitis B patients with entecavir therapy. PLoS One,2014,9:e93160.
[11] Wang JH,Changchien CS,Hung CH,et al. FibroScan and ultrasonography in the prediction of hepatic fibrosis in patients with chronic viral hepatitis. J Gastroenterol,2009,44:439-446.
[12] Yokosuka O,Takaguchi K,Fujioka S,et al. Long-term use of entecavir in nucleoside-na?ve Japanese patients with chronic hepatitis B infection. J Hepatol,2010,52:791-799.
[13] Shim,Han Chu Lee,Kang Mo Kim,et al. Efficacy of entecavir in treatment-naive patients with hepatitis B virus-related decompensated cirrhosis. J Hepatol,2010,52:176-182.
[14] Liaw YF,Raptopoulou-Gigi M,Cheinquer H,et al. Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized,open-label study. Hepatology,2011,54:91-100.
[15] Su TH,Hu TH,Chen CY,et al. Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients. Liver Int,2016,36:1755-1764.
[16] SU TH,HU TH,LIN CC,et al. Reduction of hepatocellular carcinoma in hepatitis B-related cirrhosis patients with long- term entecavir therapy-an interim report of C-team study. Hepatolo-gy,2013,58:01a.
[17] Wong GL,Chan HL,Mak CW,et al. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. Hepatology,2013,58:1537-1547.
[18] Kim SS,Hwang JC,Lim SG,et al. Effect of virological response to entecavir on the development of hepatocellular carcinoma in hepatitis B viral cirrhotic patients: comparison between compensated and decompensated cirrhosis. Am J Gastroenterol,2014,109:1223-1233.
[19] Hosaka T,Suzuki F,Kobayashi M,et al. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology,2013,58:98-107.
[20] Lo GH. Does long-term entecavir treatment really reduce hepatocellular carcinoma incidence in patients with hepatitis B virus infection？Hepatology,2014,59:2053.
[21] Lian JS,Zeng LY,Chen JY,et al. De novo combined lamivudine and adefovir dipivoxil therapy vs entecavir monotherapy for hepatitis B virus-related decompensated cirrhosis. World J Gastroenterol,2013,19:6278-6283.
[22] Peng H,Liu J,Yang M,et al. Efficacy of lamivudine combined with adefovir dipivoxil versus entecavir monotherapy in patients with hepatitis B-associated decompensated cirrhosis: A meta-analysis. J Clin Pharmacol,2014,54:189-200.
[23] Tsai MC,Yu HC,Hung CH,et al. Comparing the efficacy and clinical outcome of telbivudine and entecavir na?ve patients with hepatitis B virus-related compensated cirrhosis. Gastroenterol Hepatol,2014,29:568-575.
[24] Kim HR,Yim HJ,Kang S,et al. Efficacy of telbivudine compared with entecavir in hepatitis B virus-related cirrhosis: 2 year follow-up data. Liver Int,2015,35:860-869.
[25] Kklü S,Tuna Y,Gül?en MT,et al. Long-term efficacy and safety of lamivudine,entecavir,and tenofovir for treatment of hepatitis B virus-related cirrhosis. Clin Gastroenterol Hepatol,2013,11:88-94.
[26] Lin CL,Yang HC,Kao JH. Hepatitis B virus: new therapeutic perspectives. Liver Int,2016,36: 85-92. |
